Interpace Biosciences (IDXG) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Voting matters and shareholder proposals
Ratification of EisnerAmper, LLP as independent registered public accounting firm for fiscal year ending December 31, 2024 is up for shareholder vote.
Shareholders may transact other business as may properly come before the meeting or any adjournments.
Audit committee and external auditor matters
EisnerAmper, LLP is recommended for ratification as the external auditor for the upcoming fiscal year.
Shareholder rights and capital structure
Multiple share classes are represented for voting, including Common, Class A through F, and 401K shares.
Shareholders are encouraged to vote virtually or by proxy before the annual meeting date.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Interpace Biosciences
- Thyroid revenue rose 9% and gross margin reached 62% amid operational improvements.IDXG
Q2 2026 - Key votes include board declassification, share increase, equity plans, and auditor approval.IDXG
Proxy filing - Proxy seeks approval for governance overhaul, reverse split, new equity plans, and director elections.IDXG
Proxy filing - Key proposals include board declassification, share increase, and executive compensation approval.IDXG
Proxy filing - Virtual meeting seeks approval for charter changes, reverse split, new equity plans, and board elections.IDXG
Proxy filing - Q1 2026 revenue fell 22% but thyroid revenue grew 12% and margins improved.IDXG
Q1 2026 - Q4 and FY 2025 results highlight strong thyroid diagnostics growth and a one-time tax benefit.IDXG
Q4 2025 - Virtual annual meeting to ratify EisnerAmper as auditor; Series B holders retain key voting rights.IDXG
Proxy Filing - Record thyroid test volumes and $8.8M revenue mark Q3 amid PancraGEN® discontinuation.IDXG
Q3 2025